Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as LY231514, Alimta
Pemetrexed · 8 trials · 8 indications
dCK and hENT expression (see Outcome #2) on normal lymphocytes were measured after Pemetrexed administration to evaluate if there was reproducible timing of maximum dCK expression, and to assess proper time interval between pemetrexed and gemcitabine for treatment of patients with advanced Non-Small Cell Lung Cancer (NSCLC). Values are calculated as ratio between thereshold cycles (number of polymerase chain reaction \[PCR\] cycles) with respect to a reference gene; in this case glyceraldehyde 3-phosphate dehydrogenase (GAPDH).
dCK (see Outcome #1)and hENT expression (see Outcome #2) on normal lymphocytes were measured after Pemetrexed administration to evaluate if there was reproducible timing of maximum dCK expression, and to assess proper time interval between pemetrexed and gemcitabine for treatment of patients with advanced Non-Small Cell Lung Cancer (NSCLC). Values are calculated as ratio between thereshold cycles (number of polymerase chain reaction \[PCR\] cycles) with respect to a reference gene; in this case glyceraldehyde 3-phosphate dehydrogenase (GAPDH).
| Arm | Type | Description |
|---|---|---|
| Pemetrexed - Before Protocol Amendment | EXPERIMENTAL | - |
| Pemetrexed - After Protocol Amendment | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Pemetrexed - Before Protocol Amendment | DRUG | 500 milligrams per square meter (mg/m2), intravenous (IV), every 14 days x 8 cycles or disease progression, unacceptable toxicity or patient decision to discontinue |
| Pemetrexed - After Protocol Amendment | DRUG | 500 milligrams per square meter (mg/m2), intravenous (IV), every 21 days x 6 cycles or disease progression, unacceptable toxicity or patient decision to discontinue. |
| ALIMTA | DRUG | - |
| Carboplatin | DRUG | - |
| gemcitabine | DRUG | - |
| Oxaliplatin | DRUG | - |
| cisplatin | DRUG | - |
| folic acid | DRUG | - |
| multi-vitamins | DRUG | - |
| irinotecan | DRUG | - |
| ALIMTA plus Epirubicin | DRUG | - |
Inclusion Criteria * Histologically or cytologically proven IIIB and IV NSCLC. * No symptomatic uncontrolled brain metastasis * Not suitable for platinum containing regimens if chemo-naive * Performance status less than or equal to 2 on the Eastern Cooperative Oncology Group (ECOG) Scale. * Creatin...
Top 20 of 90 competitors
Pemetrexed- Before Protocol Amendment is an investigational small molecule studied in non-small cell lung cancer. It was evaluated in patients with locally advanced or metastatic NSCLC. The Phase 2 study enrolled adults aged 18 years and older in Italy. It is not described as an approved product.
Pemetrexed- Before Protocol Amendment is developed by Eli Lilly and Company, which trades under the ticker LLY. Eli Lilly sponsored the Phase 2 dosage schedule study of pemetrexed monochemotherapy in locally advanced or metastatic non-small cell lung cancer. The company is the named developer of this asset.
Pemetrexed- Before Protocol Amendment is in Phase 2 development. One Phase 2 trial has been completed, and no trials are currently active. The study enrolled 19 participants and has finished. Because the program remains in clinical development, it is investigational rather than an approved therapy.
Pemetrexed- Before Protocol Amendment was studied in trial NCT00370292, titled Dosage Schedule Study of Pemetrexed Monochemotherapy for Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC). The Phase 2 trial was completed, enrolled 19 participants, and was conducted in Italy. It was controlled but not randomized or double blinded.
Yes. Pemetrexed- Before Protocol Amendment is also known as Pemetrexed - Before Protocol Amendment. The two names refer to the same asset, a small molecule studied in non-small cell lung cancer. Searches using either name point to the same Phase 2 program developed by Eli Lilly and Company.
The Phase 2 trial of Pemetrexed- Before Protocol Amendment used a controlled design without randomization or double blinding. It enrolled 19 adults aged 18 years and older with locally advanced or metastatic non-small cell lung cancer in Italy. Participants were not selected by biomarker, and healthy volunteers were not included.